Adverum Biotech
Julian N Ramos has a diverse work experience in the field of biotechnology and research. Julian N is currently working as a Principal Scientist at Adverum Biotechnologies since February 2022. Previously, they served as a Senior Scientist at Ambys Medicines from February 2019 to January 2022, where they contributed to scientific advancements in the company. Prior to that, Julian worked as a Postdoctoral Scholar at UCLA from January 2015 to January 2019, focusing on investigating the roles of the immune system in muscle maintenance, regeneration, and disease. Julian N also had a role as an Undergraduate Research Assistant at Boston University School of Medicine in 2007, where they conducted research on genes involved in secondary metabolic pathways in Arabidopsis thaliana. Overall, Julian N Ramos has a strong background in biotechnology research and scientific inquiry.
Julian N Ramos completed a Bachelor of Science degree in Biochemistry from Rochester Institute of Technology from 2004 to 2008. Afterwards, they pursued a Doctor of Philosophy (Ph.D.) in Molecular and Cellular Biology at the University of Washington from 2008 to 2014.
Adverum Biotech
9 followers
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.